Determining The Impacts Of Epigenetic Modifying Drugs On Germline Programming And Offspring Health
Funder
National Health and Medical Research Council
Funding Amount
$863,918.00
Summary
New drugs have been developed that inhibit specific enzymes that regulate epigenetic pathways in cells. These pathways significantly affect growth and development in offspring and may represent a risk to future children of patients taking the drug. This project will determine these risks and provide data for developing clinical guidelines for safe use of the drugs.
A Cluster RCT Of A Novel Psychological Intervention To Reduce Depression Among At-risk Older Adults Transitioning To Residential Aged Care
Funder
National Health and Medical Research Council
Funding Amount
$893,152.00
Summary
Depression is common in aged care facilities, with many older adults finding the transition extremely difficult. We have developed a simple intervention to help new residents, including those with dementia, to adjust to life in aged care. This program focuses on key aspects of psychological wellbeing, and is designed for widespread use in aged care. We will evaluate the intervention to determine if it is superior to current care approaches in reducing depression and improving quality of life.
Development Of Vinorelbine As A Tablet Based Therapy To Cure Ectopic Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$361,594.00
Summary
Ectopic pregnancies occur if the pregnancy implants in the Fallopian tube. They can be deadly and most are treated surgically. We will examine the exciting possibility that instead of surgery, ectopic pregnancies may be cured with a tablet taken just once. We will perform laboratory studies and a clinical trial, giving vinorelbine to women with ectopic pregnancies.
Engineering MYCN Models Of High-grade Serous Ovarian Cancer (HGSC)
Funder
National Health and Medical Research Council
Funding Amount
$797,478.00
Summary
The most lethal type of ovarian cancer, high-grade serous cancer (HGSC), can be divided into four subtypes based on gene patterns. One subtype involves a set of genes/proteins that, in their specific combination, result in activation of a pathway known as MYCN. As most HGSC start in the fallopian tube, we are using fallopian tube material to make new MYCN HGSC models to observe development in the earliest stages. We hope to generate new tests and treatments for this subtype of ovarian cancer.
The N-ICE Trial: A Randomised Controlled Trial Of The Safety And Efficacy Of N-Acetyl Cysteine (NAC) As A Pharmacotherapy For Methamphetamine (“ice”) Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,551,368.00
Summary
Crystalline methamphetamine (aka ‘ice’) is a significant public health concern in Australia and globally. Currently there are no approved medications to treat methamphetamine dependence. We will trial tN-acetyl-cysteine (NAC) as a medications for methamphetamine dependence.
High-Throughput Discovery Of Synergistic Drug Combinations For Metastatic Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,526,568.00
Summary
Treatment outcomes for patients with metastatic bowel cancer remain poor, with most tumours developing resistance within 24 months. A key problem is that cancers are genetically diverse, with some cells inevitably resistant to any given treatment. This study aims to discover effective drug combinations targeting distinct essential tumour cell functions through robotics-based pairwise testing of known drugs on bowel cancer cell lines representing the genetic diversity of the disease.
A Randomised Controlled Trial Of Cognitive Bias Modification Training During Early Recovery From Alcohol Dependence
Funder
National Health and Medical Research Council
Funding Amount
$531,685.00
Summary
Relapse to alcohol dependence often occurs within days of detoxification, partly because alcohol-dependent people are easily triggered to approach alcohol-related cues. Computerised “brain-training” programs may reduce this “approach bias”, reducing risk of relapse. We aim to conduct a multi-site trial testing the effects of this training on alcohol relapse, and to estimate the savings to the health care system that could be achieved by conducting this treatment during inpatient detoxification.
Regulation Of TNF Expression In Inflammation And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$728,447.00
Summary
By studying a spontaneous mutation in mice, we have found an error in the TNF gene (a major factor in many inflammatory diseases) that causes severe arthritis, heart valve disease and gut inflammation. We have also identified new regulators of TNF expression, which might be useful therapeutic targets to limit inflammation. We intend to study the role of these regulators in controlling the expression of TNF, and the link between chronic inflammation and the development of cancer.
Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
Improving Quality Of Life In Late Stage Bipolar Disorder: RCT Of A Novel Psychological Treatment
Funder
National Health and Medical Research Council
Funding Amount
$1,083,620.00
Summary
Hundreds of thousands of Australians have bipolar disorder and receive minimal benefit from existing drug and psychological treatments. ORBIT 2.0 is a new low-intensity online treatment using mindfulness strategies to improve quality of life in this poorly served ‘late stage’ group. Pilot testing suggests ORBIT is effective. This project will refine the intervention and is expected to confirm its clinical and cost effectiveness prior to international roll-out.